GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (NAS:TRAW) » Definitions » E10

TRAW (Traws Pharma) E10 : $-19,657.80 (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Traws Pharma's adjusted earnings per share data for the three months ended in Sep. 2024 was $-8.810. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-19,657.80 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-12-11), Traws Pharma's current stock price is $5.15. Traws Pharma's E10 for the quarter that ended in Sep. 2024 was $-19,657.80. Traws Pharma's Shiller PE Ratio of today is .


Traws Pharma E10 Historical Data

The historical data trend for Traws Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma E10 Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -64,686.30 -56,903.70 -36,006.10

Traws Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41,194.20 -36,006.10 -30,232.70 -24,687.40 -19,657.80

Competitive Comparison of Traws Pharma's E10

For the Biotechnology subindustry, Traws Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Shiller PE Ratio falls into.



Traws Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Traws Pharma's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-8.81/133.0289*133.0289
=-8.810

Current CPI (Sep. 2024) = 133.0289.

Traws Pharma Quarterly Data

per share eps CPI Adj_EPS
201412 -34,732.500 99.070 -46,638.137
201503 -32,059.700 99.621 -42,810.877
201506 -23,199.500 100.684 -30,652.408
201509 -13,950.100 100.392 -18,485.295
201512 7,061.950 99.792 9,413.978
201603 -14,866.500 100.470 -19,684.147
201606 -11,049.300 101.688 -14,454.752
201609 -1,331.390 101.861 -1,738.775
201612 -4,535.390 101.863 -5,923.051
201703 -6,918.680 102.862 -8,947.742
201706 -1,631.230 103.349 -2,099.687
201709 -3,974.980 104.136 -5,077.872
201712 -3,292.480 104.011 -4,211.041
201803 -1,889.990 105.290 -2,387.924
201806 -412.498 106.317 -516.138
201809 -352.498 106.507 -440.277
201812 -318.748 105.998 -400.033
201903 -483.748 107.251 -600.020
201906 -224.999 108.070 -276.964
201909 -281.249 108.329 -345.375
201912 -19.386 108.420 -23.786
202003 -11.250 108.902 -13.742
202006 -16.250 108.767 -19.875
202009 -13.000 109.815 -15.748
202012 -13.000 109.897 -15.736
202103 -8.000 111.754 -9.523
202106 -6.750 114.631 -7.833
202109 -5.500 115.734 -6.322
202112 -4.000 117.630 -4.524
202203 -5.000 121.301 -5.483
202206 -4.750 125.017 -5.054
202209 -6.500 125.227 -6.905
202212 -6.500 125.222 -6.905
202303 -7.000 127.348 -7.312
202306 -5.000 128.729 -5.167
202309 -5.640 129.860 -5.778
202312 -4.910 129.419 -5.047
202403 -6.000 131.776 -6.057
202406 -121.750 132.554 -122.186
202409 -8.810 133.029 -8.810

Add all the adjusted EPS together and divide 10 will get our e10.


Traws Pharma  (NAS:TRAW) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Traws Pharma E10 Related Terms

Thank you for viewing the detailed overview of Traws Pharma's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma Business Description

Traded in Other Exchanges
N/A
Address
12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.
Executives
Victor M Moyo officer: CHIEF MEDICAL OFFICER 12 PENNS TRAIL, NEWTOWN PA 18940
Trafford Clarke director 12 PENNS TRAIL, NEWTOWN PA 18940
Peter Atadja director 12 PENNS TRAIL, NEWTOWN PA 18940
Abraham N. Oler officer: VP Corp Dev & Gen Counsel C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052
Steven M Fruchtman officer: Chief Medical Officer 375 PHEASANT RUN, NEWTOWN PA 18940
James J Marino director C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Gelder Mark S. Md officer: Chief Medical Officer C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark Patrick Guerin officer: Chief Accounting Officer 375 PHEASANT RUN, NEWTOWN PA 18940
Mary Teresa Shoemaker director 375 PHEASANT RUN, NEWTOWN PA 18940
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831
E Premkumar Reddy director 375 PHEASANT RUN, NEWTOWN PA 18940
Jerome Groopman director C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922
Viren Mehta director OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747
Tyndall Capital Partners L P 10 percent owner 150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022